Benzinga | Jan 29, 2021 07:40AM EST

JP Morgan Upgrades Lexicon Pharmaceuticals to Neutral, Announces $7 Price Target

JP Morgan analyst Jessica Fye upgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) from Underweight to Neutral and announces $7 price target.